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Abstract
Introduction: Neurological immune-related adverse events are a rare but potentially deadly 
complication after immune checkpoint inhibitor (ICI) treatment. As multiple sclerosis (MS) is an 
immune mediated disease it is unknown how ICI treatment may affect outcomes.
Methods: We analyzed the United States Food and Drug Administration (FDA) Adverse Event 
Reporting System (FAERS) database for pembrolizumab, atezolizumab, nivolumab, ipilimumab, 
avelumab, and durvalumab two years prior their FDA approval until December 31, 2017, to 
include all cases with confirmed diagnosis/relapse of MS. We also included cases reported in the 
literature and a patient from our institution.
Results: We identified 14 cases of MS with median age of presentation of 52 years. Indications 
for ICI included melanoma in 7 (36.36%) cases, non-small cell lung carcinoma in 2 (18.18%) 
cases, 1 case (9.09%) each of pleural mesothelioma, renal cell carcinoma, and colorectal cancer, 
and unreported in 2 (18.18%) cases. History of MS was confirmed in 8 (57.1%) cases. Median 
time to beginning of symptoms was 29 days with rapid disease progression; 2 patients died due to 
their relapse. Median time for symptom resolution was 8 weeks. Outcomes did not vary by 
comparing CTLA-4 and PD-1/PD-L1 inhibitors.
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Conclusions: Reported MS relapses after ICI are rare but the adverse events described include 
rapid neurologic progression and death. Larger and prospective studies are warranted to assess 
disability and long-term outcomes and outweigh the risks of starting immunotherapy in patients 
with MS.
Keywords
1-Multiple sclerosis; 2-immune checkpoint inhibitors; 3-immune related adverse events
INTRODUCTION
Immune checkpoint inhibitors (ICI) include CTLA-4 and PD-1/PD-L1 inhibitors and have 
recently become the standard of care for a growing list of cancers, including melanoma, non-
small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, 
urothelial carcinoma, and microsatellite instability-high solid tumors[2, 4, 5, 9, 16, 24, 28, 
34, 35]. Immunotherapies differ from conventional chemotherapy as they are not directly 
cytotoxic, but are designed to engage the immune system to generate antitumor activity[13]. 
CTLA-4 and PD-1/PD-L1 are ligands to the B7 costimulatory pathway that mediate T-cell 
inhibition[19]. Due to their mechanisms of action, ICI have been associated with a unique 
spectrum of immune related adverse events (irAEs) by deregulating the response of T cells 
to antigens presented by normal cells. A possibility exists for immune mediated diseases, 
such as multiple sclerosis (MS), to be triggered or significantly aggravated with the use of 
these medications[6, 10]. However, knowledge on the neurological irAEs is still insufficient 
due to the novelty of these drugs.
MS affects more than 400,000 people in the United States, presenting with an array of 
clinical presentations that include vision loss, limb weakness, sensory abnormalities, or 
ataxia[1]. Several studies support an inflammatory patient-dependent immune-mediated 
component for MS[27, 43], with genetic and environmental risk factors identified[3], and a 
T-cell mediated pathogenesis mechanistically similar to ICI[22, 39].
Neurological complaints are one of the most common reasons for hospital admission in 
cancer patients[31]. Severe neurological irAEs with ICI therapy have been reported in less 
than 1% of patients[23, 40, 42, 45]. The majority of neurological irAEs manifest 
predominantly as peripheral neuropathy and are generally associated with a benign course[8, 
25]. MS is the most common cause of permanent disability in young adults[30, 33], with 
limited response to treatment. Future functional impairment is a major concern if a relapse 
develops during ICI therapy, more so than with other neurological irAEs.
No study has focused on the outcomes of MS patients after ICI therapy, and with an 
increasing approval of ICI use safety in these patients will be an important clinical question. 
Due to the heterogeneity of MS, response after ICI may be unpredictable. We analyzed the 
outcomes of documented cases of MS relapse after treatment with ICI in a comprehensive 
analysis of the available published literature, the Food and Drug Administration (FDA) 
Adverse Event Reporting System (FAERS) database, and our institutional experience.
Garcia et al. Page 2
Clin Transl Oncol. Author manuscript; available in PMC 2020 October 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
METHODS
We present one case from our institution, a review of the published literature, and the 
FAERS database for patients who developed MS relapse during cancer therapy with ICI. 
FAERS data was provided by the FDA upon request.
Search strategy
Institutional—We performed a retrospective analysis of cancer patients that received at 
least one cycle of pembrolizumab, atezolizumab, nivolumab, ipilimumab, avelumab, and/or 
durvalumab during any part of their cancer treatment and that had a history of MS that 
developed symptoms during or after their therapy with ICI. Only 1 patient was identified 
from this search.
FAERS—We analyzed the FAERS database for pembrolizumab, atezolizumab, nivolumab, 
ipilimumab, avelumab, and durvalumab from 2 years before their FDA approval until 
December 31, 2017, to include all cases with confirmed diagnosis of MS. After case 
identification, detailed reports were requested to the FDA and information is presented as 
available in those reports. Multiple reports that described the same patient were grouped 
together.
FAERS is an international database maintained by the FDA that collects de-identified 
information on adverse event reports, medication error, and product quality complaints. 
Reports are limited to the information disclosed by the reporter, which includes health care 
providers, drug manufacturers, and consumers. Information included in these reports details 
drug exposure, disease indications, and clinical outcomes[36, 37]. FAERS is a reliable 
source of information that has been used extensively by researchers and our group in several 
areas to describe post-marketing surveillance of medications[15]. It provides a unique 
opportunity to assess cases globally with detailed reports of their event.
Based on FDA regulations, outcomes are reported in the following categories: congenital 
anomaly/birth defect, death, disability, hospitalization, life threatening, other serious 
important medical event, and required intervention to prevent permanent impairment/
damage. OT is defined as an outcome that does not fit other categories, but may jeopardize 
patients requiring medical or surgical intervention to prevent one of the other outcomes.
Literature—We performed a systematic review of the literature using the PubMed 
database. We searched for all published literature regarding MS and nivolumab, ipilimumab, 
atezolizumab, pembrolizumab, avelumab, or durvalumab use until April 11, 2018. Our 
search included combinations of the keyword “multiple sclerosis” with “nivolumab”, 
“ipilimumab”, “atezolizumab”, “pembrolizumab”, “durvalumab”, and “avelumab”. Two 
researchers performed this search independently for internal validity. Only three articles 
were found[6, 10, 11], and were reviewed in full-text form. No language, time, age, or date 
filters were included in our search.
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Statistics
Categorical variables are presented in frequency and percentages. Continuous variables are 
presented with medians. Results were compared using Fisher’s exact tests and Wilcoxon 
Rank Sum tests presented as p-values. The level of statistical significance was set at 0.05 for 
all tests conducted, and all analyses were performed with SPSS software version 23.
RESULTS
Our analysis of FAERS captured 42,529 adverse events with the use of ICI with 13 cases 
identified with MS. In the published literature our search identified three cases, but they 
were matched to cases in FAERS, as they contained identical clinical and treatment history, 
and were not counted as additional cases. We present an additional case from our practice 
further below.
The median age of presentation for MS cases identified was 52.5 years. ICI were used in the 
following indications (cancer type): melanoma (n=7), non-small cell lung carcinoma in 
(n=2), pleural mesothelioma (n=1), renal cell carcinoma (n=1), and colo-rectal cancer (n=1). 
The indication was not reported in 2 patients.
The ICI with higher number of reported cases of MS was nivolumab (n=9), followed by 
ipilimumab (n=5), pembrolizumab (n=2), and atezolizumab (n=1). No cases were attributed 
to durvalumab or avelumab. We found no differences while comparing agents or mechanism 
of action (PD-1 axis versus CTLA-4 inhibitors) between demographics or outcomes 
variables. History of MS was confirmed in 8 patients. One patient had a history of vitiligo, 
otherwise an autoimmune disorder history was negative or unknown. All of the patients had 
diagnosis of metastatic disease. Previous cancer therapy is largely unknown, but the cases 
that reported it received several courses of chemotherapy, surgery, and radiation prior to 
beginning immunotherapy. MS treatment was reported in 4 patients, 3 of which were 
previously receiving glatiramer acetate, and 1 patient was receiving interferon-beta. Of these 
patients, three were not receiving MS treatment while on ICI. The reason was to avoid 
possible interference with the mechanism of action (2 patients), withholding therapy before 
starting ICI, and because the diagnosis of MS was not clear before ICI therapy (1 patient).
Clinical presentation varied from paresthesias, vision changes, weakness, and altered mental 
status (table 2). A detailed description of the clinical presentation of case 10, 11, and 14 is 
available in the literature[6, 10, 11], and case 5 was presented at the Society for Neuro 
Oncology Annual Meeting in 2016[12]. The basis for the diagnosis of MS was reported in 8 
cases and was based on combination of clinical presentation, MRI brain studies (8 cases), 
biopsy (2 cases), and cerebrospinal fluid analyses (2 cases). Median time to symptom onset 
was 29 (12–120) days, with a median of 2 cycles to onset. Patients receiving CTLA-4 
inhibitors had a numerically higher median time to onset of event, and number of cycles 
compared to PD-1/PD-L1 inhibitors, but was not statistically significant (Table 1). In all 
cases, the drug was discontinued when the clinical diagnosis of MS was clear. One patient 
was re-treated with ipilimumab after presenting mild symptoms of MS relapse, due to the 
beneficial cancer response. His MS symptoms significantly worsened following retreatment 
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and his re-trial was discontinued. In two other cases, the course of MS relapse was 
particularly serious, with rapid progression and poor response to MS therapy.
Therapy for MS relapse was provided for 5 patients who received IV corticosteroids. 
Patients were not reported to have received any form of immunotherapy prior to or during 
immune checkpoint inhibitor administration. Symptom resolution was reported in 5 patients, 
with 3 patients presenting MS progression and significant disability, including 2 patients 
who died from their disease. Overall median duration of event as 56 (21–112) days. Median 
symptom duration was 4 weeks for PD axis inhibitors, with a trend to longer duration in 
CTLA-4 inhibitors that was not statistically significant (12 weeks compared to 4 weeks, 
p=0.700) (Table 2). All cases presented with other serious adverse events and 4 patients 
required hospitalization.
Case Report
A 49-year-old woman with a history of relapsing remitting MS since 2003, and metastatic 
colonic adenocarcinoma since January 2015. She received off label use of atezolizumab with 
cobimetinib, a reversible inhibitor of mitogen-activated protein kinase/extracellular signal 
regulated kinase (MEK), in August 2016. Two weeks following single treatment she 
presented to the ED with a 3-day history of persistent fever and progressing confusion. She 
was admitted and underwent workup including brain and body imaging, laboratory tests, and 
cerebrospinal fluid (CSF) analysis. The laboratory workup was negative except for mild 
residual neutropenia and hyponatremia, and an increased total protein in CSF. An infectious 
cause was ruled out. Brain MRI on September 2016 demonstrated nonspecific T2 
hyperintense lesions within the subcortical, deep, and periventricular white matter. No 
leptomeningeal enhancement was evident in the images. A presumptive diagnosis of MS 
relapse was made based on her history.
The patient’s MS had been treated regularly with glatiramer acetate since 2009, with her last 
MS relapse in 2014. She was using glatiramer during her treatment with atezolizumab. Her 
cancer had been treated aggressively with multiple lines of chemotherapy, and surgical 
procedures (right colectomy, liver sectionectomy, and right hepatic artery 
radioembolization). Chemotherapy included FOLFOXIRI [5-fluorouracil (5-FU)/leucovorin, 
oxaliplatin, irinotecan] plus bevacizumab, 5-FU and bevacizumab, trifluridine and tipiracil, 
FOLFIRI (folinic acid, 5-FU, and irinotecan) plus bevacizumab, and regorafenib. The MS 
relapse being attributable to atezolizumab therapy was deemed probable based on the 
Naranjo Algorithm for Adverse Drug Reaction Probability Scale (Score=6)[29]. Her 
neurological status continued to deteriorate, showing no response to high-dose 
corticosteroids or supportive measures. Follow up imaging demonstrated a decreased size of 
liver metastases, but suspected disease progression versus pseudoprogression in the chest. 
Therapy was withheld due to her clinical status and she passed away a month after her first 
dose of atezolizumab.
DISCUSSION
Immune checkpoint inhibitors are thought to induce epitope spreading and a broader T cell 
response[22, 39], that may trigger immune-mediated syndromes. Previous analyses have 
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demonstrated similar proliferation rates and pro-inflammatory cytokine production of 
myelin-reactive CD4+ T cells from ipilimumab treated patients, comparable to patients with 
MS[6]. In addition, in patients with a history of kidney transplantation that received 
ipilimumab, T-cell mediated graft rejection has been described[44].
The outcomes of patients presenting with neurological irAEs are thought to be favorable[7, 
32], however there are few severe reactions described with severe organ failure leading to 
death[7, 8, 46]. Out of the fourteen cases, eight had a reported history of MS. The frequency 
of clinically isolated or radiographically isolated syndrome in patients that received 
immunotherapy is difficult to assess and would require a high level of suspicion in 
prospective studies. All of the patients in our analysis presented rapid disease progression 
requiring medical intervention, and two patients died from their MS relapse. Imaging, or 
pathological patterns, biopsy, or autopsy material was not available for our review, and is a 
limitation to FAERS data analysis.
The time to event for irAE remain an active area of investigation and may range from weeks 
to months[32]. Single center experiences and retrospective reviews describe a range of 
neurological irAEs that includes headaches, neuropathies, meningitis, and myasthenic 
syndromes[7, 18]. This literature describes a median time to event of 6–13 weeks after 
therapy, with an incidence as high as 12% for reported neurological irAEs for combinatorial 
use of anti-PD1 and anti-CTLA-4 inhibitors[7, 14, 18].
The median of 29 days in our study, with few cases successfully responding to symptomatic 
treatment, suggests a rapid and aggressive reaction. Patients in our analysis had a median 
age of 52.5 years, younger than described for other neurological irAEs (56–71 years)[7, 18]. 
No clear association between ICI agent and neurological syndromes have been described to 
date[7], and in our analysis no demographic or outcome variables were found to be different 
between ICI agents. We believe the higher number of cases of nivolumab, and the higher 
number of cases with melanoma are related to earlier FDA approval, rather than agent or 
disease specific syndrome.
Specific cancer types may have a higher predisposition of developing neurological AEs. 
Neuropathies are more commonly associated with ANNA-1 antibodies, that are seen 
primarily in small cell lung cancer, breast cancer, and renal cancer[41]. The close temporal 
relationship of immune checkpoint inhibitors administration to the development of 
symptoms and documented MRI activity provide basis to support causation of immune 
checkpoint inhibitors to the MS relapse. Similar basis is used for other drugs related adverse 
events and is validated by the Naranjo Algorithm for Adverse Drug Reaction Probability 
Scale[29].
Eight patients had a history of MS in our analysis, of which 5 reported symptom resolution. 
A history of autoimmune disorders as a contraindication for ICI therapy is under debate, as 
some patients may still benefit from immune-based cancer therapies. Yet, it is expected that 
around 30% will either experience a flare of their disease or a new immunological event, 
generally with mild severity[17, 26]. Limited evidence after solid organ transplantation 
suggests ICI should be used with caution, and may result in graft loss and life-threatening 
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events[20, 21]. However, the reduction of immunosuppression has been questioned as the 
cause of graft loss[44]. Some patients had stopped MS therapy at the time they received 
immunotherapy. Nonetheless, the effect of immunomodulation of MS is not as predictable as 
immunosuppression after transplantation. Severe, life-threatening immune-based syndromes 
have been previously described after adjuvant exposure (vaccination, systemic viral 
infection) and ICI may trigger similar presentations[38].
Disease presentation was variable between cases, but was particularly severe in 3 cases, one 
of which was seen in our institution. Our patient presented a clinical syndrome resembling 
autoimmune encephalitis, with decreased level of consciousness and rapid progression. 
Immune activation cascade may differ from patient to patient[41], but much is still unknown 
on risk factors for developing neurological irAE. As the use of ICI increases, the number of 
patients presenting these reactions will increase.
Retrospective cohorts have demonstrated an adequate cancer response in patients that 
present irAEs[17]. Only two of our cohort were re-exposed or continued treatment. 
Interestingly, the majority of cases continued to manifest MS symptoms long after stopping 
therapy (Figure 1), likely related to the long half-life of ICI[7], and a prolonged and 
sustained immune response. A history of multiple rounds of cancer treatment, as was the 
case in the majority of these patients, may increase the risk and severity of neurotoxicities.
Some of the limitations of our study include the lack of detailed MS follow up, disability 
measures, and long outcome data. Reporting bias is a significant limitation of our sample, as 
cases with worst outcomes were more likely to be reported to the FDA. Larger analyses 
might confirm outcome differences between CTLA-4 inhibitors and PD-1 axis inhibitors in 
terms of MS relapse. Our analysis demonstrates ICI therapy in patients with MS may be 
associated with rapid worsening neurological condition and death. Future longitudinal 
studies to assess worsening neurologic function in patients with MS relapse after ICI therapy 
would provide information regarding prognosis and help outweigh the risks of ICI in these 
patients.
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Figure 1. 
Swimmers plot for duration of ICI therapy and MS symptoms. The orange line depicts the 
time since starting an ICI to the time that MS symptoms began. The blue line depicts the 
duration of symptoms.
Garcia et al. Page 10
Clin Transl Oncol. Author manuscript; available in PMC 2020 October 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Garcia et al. Page 11
Table 1.
Overall demographics and characteristics by patients (TTE: Time to event)
Case Age Gender Indication ICI Hx 
of 
MS
TTE CTE Total 
Cycles
Outcome Resolution Duration
1 58 F Melanoma Pembrolizumab Yes 3 wks 1 3 OT Yes NR
2 NR M Pleural mesothelioma Pembrolizumab NR NR NR NR HO, OT No 3 mo
3 50 F Melanoma Nivolumab Yes NR NR NR OT NR NR
4 63 F NSCLC Nivolumab NR 2 mo 2 2 OT NR NR
5 43 F NSCLC Nivolumab Yes 12 d 1 1 HO, OT Yes 1 mo
6 NR NR NR Nivolumab NR NR NR NR OT NR NR
7 NR NR NR Nivolumab NR NR 2 2 OT NR NR
8 45 M RCC Nivolumab No NR NR NR OT NR NR
9 49 F Colorectal Atezolizumab Yes 2 wks 1 1 DE, HO No 1 mo
10 76 F Melanoma Ipilimumab No 4 wks 4 4 DE No 4 mo
11 29 M Melanoma Ipilimumab Yes 4 mo 8 8 OT, HO Yes 3 wks
12 55 M Melanoma Ipilimumab Yes 2 mo 3 3 OT Yes NR
13 NR M Melanoma Ipilimumab Yes NR NR NR OT NR NR
14 56 M Melanoma Ipilimumab Yes 1 mo 4 4 OT Yes 3 mo
ICI: Immune checkpoint inhibitor; Hx: History; MS: Multiple sclerosis; TTE: Time to event; CTE: Number of cycles to event; wks: Weeks; mo: 
Months; d: days
Clin Transl Oncol. Author manuscript; available in PMC 2020 October 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Garcia et al. Page 12
Table 2.
Clinical phenotype descriptions as available in the reports
Patient Clinical presentation (as described in the reports)
1 Paresthesia and decreased strength in lower and upper limbs.
3 Numbness to hand a feet and loss of bladder control.
5 Progressive diplopia, gait instability, bilateral ptosis, internuclear opthalmoplegia, and ataxic gait.
9 Fever and progressive confusion.
10 Fatigue, memory loss, and vision changes.
11 Thermhypaesthesia of both feet.
12 Left leg weakness, left arm weakness, and significant fatigue
14 Left lower extremity hemiparesis, gait dysfunction, and ataxia.
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Table 3.
Demographics and characteristics by mechanism of action of immune checkpoint inhibitor
CTLA-4 N=5 PD-1/PD-L1 N= 9 p-value
Age (years) Median 56 46 0.762
TTE (days) Median 30 13 0.114
Cycles TE Median 4 1 0.111
Total cycles Median 4 1 0.016
Duration of event (weeks) Median 12 4 0.700
N % N %
Gender Female 1 20.0% 5 55.6% 0.236
Male 4 80.0% 2 22.2%
Not reported 0 0.0% 2 22.2%
History of MS No 1 20.0% 1 11.1% 0.301
Yes 4 80.0% 4 44.4%
Not reported 0 0.0% 4 44.4%
OT No 1 20.0% 1 11.1% 0.604
Yes 4 80.0% 8 88.9%
DE No 4 80.0% 8 88.9% 0.604
Yes 1 20.0% 1 11.1%
HO No 4 80.0% 6 66.7% 0.545
Yes 1 20.0% 3 33.3%
Resolution No 1 20.0% 2 22.2% 0.513
Yes 3 60.0% 2 22.2%
Not reported 1 20.0% 5 55.6%
Corticosteroids Not reported 3 60.0% 6 66.7% 0.622
Yes 2 40.0% 3 33.3%
*
p-values are from Fisher’s exact tests and Wilcoxon Rank-Sum.
TTE: Time to event; TE: To event; MS: Multiple sclerosis; OT: Other serious complication; DE: Death; HO: Hospitalization
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